CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...

At the recent American Society of Hematology (ASH) annual meeting, phase II data were presented on a bispecific antibody for ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

Ipsen ($GB:0MH6) announced an update on their ongoing clinical study. Study Overview: Ipsen is conducting a study titled A Prospective Real-World ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Maddocks: So let ...

Lower socioeconomic status is associated with poor survival in lymphoma. Patients with follicular lymphoma (FL) lived longer if they had private insurance, according to a study that examined patient ...

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...

More than 138.3 million people are known to have contracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with over 2.9 million deaths. Jerusalem, in Israel, is a city that ...

We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. We randomly ...

Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns of care of FL in the United States. Two thousand ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision ...